Patents by Inventor Chengxi HE

Chengxi HE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AS BCL-2 INHIBITORS
    Publication number: 20230159527
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: May 7, 2021
    Publication date: May 25, 2023
    Inventors: Weipeng ZHANG, Hongbin LIU, Rui TAN, Zhifu LI, Yue RONG, Qihong LIU, Zhifang CHEN, Ling CHEN, Hua XU, Zuwen ZHOU, Jinhua YU, Haohan TAN, Bin LIU, Yunling WANG, Lijun YANG, Chengxi HE, Lihua JIANG, Shu LIN, Xingdong ZHAO, Weibo WANG
  • COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20230145305
    Abstract: Provided are certain BTK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: March 10, 2021
    Publication date: May 11, 2023
    Inventors: Chengxi HE, Xianlong WANG, Yue RONG, Rui TAN, Huajie ZHANG, Haohan TAN, Yanxin LIU, Shu LIN, Tongshuang LI, Xingdong ZHAO, Weibo WANG
  • COMPOUNDS AS CDK2/4/6 INHIBITORS
    Publication number: 20230135215
    Abstract: Provided are certain CDK2/4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: February 26, 2021
    Publication date: May 4, 2023
    Inventors: Huajie ZHANG, Hua XU, Chengxi HE, Ling CHEN, Lijun YANG, Lihua JIANG, Shu LIN, Xingdong ZHAO, Weibo WANG
  • Macrocyclic compounds as TRK kinases inhibitors
    Patent number: 11555042
    Abstract: Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: January 17, 2023
    Assignee: Fochon Biosciences, Ltd.
    Inventors: Huajie Zhang, Qihong Liu, Chengxi He, Weipeng Zhang, Rui Tan, Bin Liu, Hong Fu, Haohan Tan, Lijun Yang, Hongbin Liu, Yunling Wang, Yuwei Gao, Zongyao Zou, Yanxin Liu, Shu Lin, Tongshuang Li, Xingdong Zhao, Weibo Wang
  • APOPTOSIS-INDUCING AGENTS
    Publication number: 20220402913
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: July 15, 2021
    Publication date: December 22, 2022
    Inventors: Hongbin LIU, Yue RONG, Huajie ZHANG, Zhifang CHEN, Rui TAN, Chengxi HE, Zhifu LI, Zuwen ZHOU, Haohan TAN, Kai RAN, Xianlong WANG, Zongyao ZOU, Lihua JIANG, Yanxin LIU, Xingdong ZHAO, Weibo WANG, Jiemin FU
  • Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors
    Patent number: 11459332
    Abstract: Provided are certain TRK inhibitors of formula (I): pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: October 4, 2022
    Assignee: Fochon Biosciences, Ltd.
    Inventors: Hongbin Liu, Haohan Tan, Chengxi He, Xianlong Wang, Qihong Liu, Zhifu Li, Zuwen Zhou, Yuwei Gao, Lihua Jiang, Li Linghu, Shu Lin, Xingdong Zhao, Weibo Wang
  • SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20220041588
    Abstract: Provided are certain RET inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 10, 2022
    Inventors: Chengxi HE, Rui TAN, Zuwen ZHOU, Weipeng ZHANG, Yunling WANG, Qihong LIU, Xingdong ZHAO, Yanxin LIU, Yuwei GAO, Shu LIN, Weibo WANG
  • Apoptosis-inducing agents
    Patent number: 11091478
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: August 17, 2021
    Assignee: Fochon Pharmaceutical Co., Ltd.
    Inventors: Hongbin Liu, Yue Rong, Huajie Zhang, Zhifang Chen, Rui Tan, Chengxi He, Zhifu Li, Zuwen Zhou, Haohan Tan, Kai Ran, Xianlong Wang, Zongyao Zou, Lihua Jiang, Yanxin Liu, Xingdong Zhao, Weibo Wang, Jiemin Fu
  • Compounds as BLC-2-selective apoptosis-inducing agents
    Patent number: 11053239
    Abstract: Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: July 6, 2021
    Assignee: Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong Zhao, Zuwen Zhou, Chengxi He, Zhifu Li, Yue Rong, Rui Tan, Huajie Zhang, Hongbin Liu, Weipeng Zhang, Haohan Tan, Zhifang Chen, Lihua Jiang, Yanxin Liu, Min Lin, Jing Sun, Weibo Wang
  • MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS
    Publication number: 20210139506
    Abstract: Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: March 27, 2019
    Publication date: May 13, 2021
    Applicants: Fochon Pharmaceuticals, Ltd., Shanghai Fochon Pharmaceutical Co., LTD.
    Inventors: Huajie ZHANG, Qihong LIU, Chengxi HE, Weipeng ZHANG, Rui TAN, Bin LIU, Hong FU, Haohan TAN, Lijun YANG, Hongbin LIU, Yunling WANG, Yuwei GAO, Zongyao ZOU, Yanxin LIU, Shu LIN, Tongshuang LI, Xingdong ZHAO, Weibo WANG
  • SUBSTITUTED (2-AZABICYCLO[3.1.0]HEXAN-2-YL)PYRAZOLO[1,5-a]PYRIMIDINE AND IMIDAZO[1,2-b]PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS
    Publication number: 20210024528
    Abstract: Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 28, 2021
    Inventors: Hongbin LIU, Haohan TAN, Chengxi HE, Xianlong WANG, Qihong LIU, Zhifu LI, Zuwen ZHOU, Yuwei GAO, Lihua JIANG, Li LINGHU, Shu LIN, Xingdong ZHAO, Weibo WANG
  • APOPTOSIS-INDUCING AGENTS
    Publication number: 20200115379
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 17, 2018
    Publication date: April 16, 2020
    Inventors: Hongbin LIU, Yue RONG, Huajie ZHANG, Zhifang CHEN, Rui TAN, Chengxi HE, Zhifu LI, Zuwen ZHOU, Haohan TAN, Kai RAN, Xianlong WANG, Zongyao ZOU, Lihua JIANG, Yanxin LIU, Xingdong ZHAO, Weibo WANG, Jiemin FU
  • COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS
    Publication number: 20190345156
    Abstract: Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bc1-2 inhibitors can be used to treat cell proliferative disorders.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 14, 2019
    Applicants: Shanghai Fochon Pharmaceutical Co., Ltd., Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong ZHAO, Zuwen ZHOU, Chengxi HE, Zhifu LI, Yue RONG, Rui TAN, Huajie ZHANG, Hongbin LIU, Weipeng ZHANG, Haohan TAN, Zhifang CHEN, Lihua JIANG, Yanxin LIU, Min LIN, Jing SUN, Weibo WANG